Atara Biotherapeutics, Inc.

clinical-stage biotechnology company

ATRA Nasdaq SEC CIK 1604464 LEI 549300WBXUXZRE03MS38
Follow Atara Biotherapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $1.2M −64.6% vs same quarter last year
Net income −$2.2M +48.2% vs same quarter last year
EPS, diluted −$0.15 +53.1% vs same quarter last year
Operating cash flow −$879K +91% vs same quarter last year
Revenue by quarter
$32.8M
$98.1M
$17.6M
$3.5M
$1.6M
$516K
$630K
$1.2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income14 fiscal years
  • Revenue
  • Net income
−$400M−$200M$0$200MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$120.8M$32.7M
FY24$128.9M−$85.4M
FY23$8.6M−$276.1M
FY22$63.6M−$228.3M
FY21-−$340.1M
FY20-−$306.6M
FY19-−$291M
FY18-−$230.7M
FY17-−$119.5M
FY16-−$79M
FY15-−$57.2M
FY14-−$28M
FY13-−$8.8M
FY12--
MarginsShare of revenue
  • Operating margin
  • Net margin
−4000%−3000%−2000%−1000%0%1000%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY2529.7%27.1%
FY24−64.7%−66.2%
FY23−3219.5%−3220.9%
FY22−441.2%−359.1%
FY21--
FY20--
FY19--
FY18--
FY17--
FY16--
FY15--
FY14--
FY13--
FY12--
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$50.9M
FY24−$69M
FY23−$194.2M
FY22−$274.6M
FY21−$231.1M
FY20−$185.3M
FY19−$241.4M
FY18−$215.7M
FY17−$107.7M
FY16−$63M
FY15−$37.4M
FY14−$16.7M
FY13−$6M
FY12-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Atara Biotherapeutics
  • Healthcare median
−4000%−3000%−2000%−1000%0%1000%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearAtara BiotherapeuticsHealthcare median
FY2527.1%−30.6%
FY24−66.2%−47%
FY23−3220.9%−58%
FY22−359.1%−80.4%
FY21-−71.8%
FY20-−62.2%
FY19-−46.2%
FY18-−49.6%
FY17-−45.9%
FY16-−36%
FY15-−37.8%
FY14-−35.5%
FY13-−37.1%
FY12-−29.1%